Who owns BridgeBio Pharma, Inc.?
Prices and market caps: Cboe delayed data, at least 15 minutes delayed. Not real-time. Fundamentals from company filings.
Institutional ownership of BBIO from SEC Form 13F filings across 471 reporting managers. All positions are from one synchronized reporting period — 2026-09-30 books, filed up to 45 days after quarter end — so every row is comparable.
As of the 2026-09-30 reporting period, 471 institutions disclosed 191.8M shares of BridgeBio Pharma, Inc. worth $12.66B — about 97.9% of shares outstanding; the largest disclosed holder is Janus Henderson Group Ltd.. Source: SEC Form 13F filings, parsed by EvidInvest.
471
13F holders
$12.66B
value, 2026 filers
97.9%
of shares outstanding (191.8M sh)
68
new positions (2026 filers)
Top institutional holders
ordered by shares owned · positions as of 2026-09-30 · % of fund = share of the manager's own book · % of co. = share of BBIO's shares outstanding
| # | Manager | Shares | Value | % of fund | % of co. | Δ shares QoQ |
|---|---|---|---|---|---|---|
| 1 | Janus Henderson Group Ltd.NEW | 14.6M | $957.7M | 0.4% | 7.4% | new |
| 2 | FARALLON CAPITAL MANAGEMENT, L.L.C. | 14.2M | $937.5M | 4.0% | 7.3% | +32.6% |
| 3 | BlackRock, Inc. | 10.4M | $683.6M | 0.0% | 5.3% | +1.0% |
| 4 | VIKING GLOBAL INVESTORS LP | 9.8M | $644.3M | 2.0% | 5% | -1.6% |
| 5 | WELLINGTON MANAGEMENT GROUP LLP | 9.5M | $622.4M | 0.1% | 4.8% | +78.2% |
| 6 | Kohlberg Kravis Roberts & Co. L.P. | 8.3M | $543.6M | 10.8% | 4.2% | -37.7% |
| 7 | VANGUARD CAPITAL MANAGEMENT LLC | 7.9M | $520.7M | 0.0% | 4% | +0.2% |
| 8 | VANGUARD PORTFOLIO MANAGEMENT LLC | 7.5M | $492.5M | 0.0% | 3.8% | -2.2% |
| 9 | STATE STREET CORP | 5.0M | $327.5M | 0.0% | 2.5% | +12.2% |
| 10 | Invesco Ltd. | 4.3M | $284.1M | 0.0% | 2.2% | +16.6% |
| 11 | JPMORGAN CHASE & CO | 4.0M | $264.5M | 0.0% | 2% | +66.8% |
| 12 | TWO SIGMA INVESTMENTS, LP | 3.7M | $240.8M | 0.2% | 1.9% | -22.5% |
| 13 | FRANKLIN TEMPLETON INC | 3.3M | $255.4M | 0.1% | 1.7% | +51.8% |
| 14 | GEODE CAPITAL MANAGEMENT, LLC | 3.3M | $215.8M | 0.0% | 1.7% | -4.1% |
| 15 | Aisling Capital Management LP | 3.1M | $203.3M | 67.9% | 1.6% | -32.7% |
| 16 | ADAGE CAPITAL PARTNERS GP, L.L.C. | 3.0M | $199.5M | 0.3% | 1.5% | +34.6% |
| 17 | UBS Group AG | 2.5M | $166.0M | 0.0% | 1.3% | +43.6% |
| 18 | Paradigm Biocapital Advisors LPNEW | 2.3M | $154.5M | 3.1% | 1.2% | new |
| 19 | D. E. Shaw & Co., Inc. | 2.2M | $146.3M | 0.1% | 1.1% | -38.8% |
| 20 | Polar Capital Holdings Plc | 2.2M | $141.5M | 0.3% | 1.1% | +4.2% |
| 21 | MANUFACTURERS LIFE INSURANCE COMPANY, THE | 2.0M | $128.4M | 0.1% | 1% | -0.3% |
| 22 | SC US (TTGP), LTD. | 1.9M | $122.4M | 0.5% | 0.9% | 0.0% |
| 23 | PRICE T ROWE ASSOCIATES INC /MD/ | 1.7M | $114.8M | 0.0% | 0.9% | +1.1% |
| 24 | CITADEL ADVISORS LLC | 1.7M | $113.5M | 0.0% | 0.9% | -54.1% |
| 25 | PRIMECAP MANAGEMENT CO/CA/ | 1.7M | $111.8M | 0.1% | 0.9% | +67.3% |
Source: SEC Form 13F-HR filings (institutional managers over $100M in US-listed positions). 13Fs disclose long positions only, up to 45 days after quarter end; each manager's latest filed quarter is shown per row and dollar values are the manager's filed marks. Aggregates labeled "2026 filers" count only managers whose latest book is a 2026 quarter. Related: valuation · options positioning · supply chain. Research, not investment advice.